---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-25-000011"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:57:50.050183+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat

## Summary
- Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).
- Q4 operating loss $49.8M, net loss $49.0M (unchanged YoY).
- Full year 2024 net loss $182.6M, improved from $255.1M loss in 2023.
- FY2025 revenue guidance $610M-$630M (0-3% growth); midpoint implies double-digit growth for Chromium and spatial.
- Cash and securities $393.4M; launched Billion Cells Project with CZI and Ultima Genomics.

## SEC filing metadata
- accession: 0001770787-25-000011
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/0001770787-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/txg-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-25-000011
- JSON: https://secwatch.observer/filing/0001770787-25-000011.json
- Plain text: https://secwatch.observer/filing/0001770787-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.